Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[F-18]RGD-K5 PET in Carotid Artery Stenosis
NCT01602471Phase 2
Key facts
- Status
- Terminated
- Start
- May 2012
- Primary completion
- Mar 2013
- Countries
- 1
- Sponsor
- Siemens AG
- Modality
- Peptides
- Drugs
- flotegatide
- Conditions
- carotid artery stenosis
01
Overview
Phase 2, open-label, single-arm trial of flotegatide in carotid artery stenosis, sponsored by Siemens AG. Primary endpoint: [F-18]RDG-K5 Uptake by Carotid Plaque on PET Scan at Day 1. Started May 2012; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
[F-18]RDG-K5
Participants receive [F-18]RGD-K5 and undergo PET imaging followed by CEA.
03
Endpoints
Primary
[F-18]RDG-K5 Uptake by Carotid Plaque on PET Scan
Beyond the preview
Go deeper on NCT01602471.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602471.